“Viscadia brought additional dimensions to the existing forecast, which aided buy in from our stakeholders. I needed someone to work alongside me, and they were the ideal partner.”

Rob Hernandez Senior Director Forecasting & Financial Planning, Daiichi-Sankyo, Inc.

“Viscadia has been a long-term strategic partner to Milestone on the forecasting front. In addition to their responsiveness and innovative modeling techniques, they have deep therapeutic expertise which enables us to expand our own thinking and ultimately make more informed decisions.”

Lorenz Muller Chief Commercial Officer, Milestones Pharmaceuticals, Inc.

“Our forecast was accurate… that was a critical piece of allowing us to complete a successful and valuable acquisition.”

Josh Franklin President, Pharmacosmos Therapeutics Inc.

“Across multiple projects, Viscadia has listened to our needs and prioritized delivery of key insights that help us gain alignment with the broader team. Their specialization in oncology forecasting has made each forecast creation a breeze, and expanding and updating our models has been seamless. In rapidly changing therapeutic areas, Viscadia’s forecasts have withstood the test of time!”

Sarah Yue Director, Oncology HCP Marketing, Pfizer